An evidence-based model to consolidate medication adherence cost estimation: The medication adherence cost estimation framework

Cutler, RL; Der Linden, NV; Benrimoj, SIC; Fernandez-Llimos, F; Garcia-Cardenas, V

An evidence-based model to consolidate medication adherence cost estimation: The medication adherence cost estimation framework

Cutler, RL

Der Linden, NV Benrimoj, SIC

Fernandez-Llimos, F

Garcia-Cardenas, V

Permalink

Publication Type:: Journal Article
Citation:: Journal of Comparative Effectiveness Research, 2019, 8 (8), pp. 555 - 567
Issue Date:: 2019-06-01

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Accepted Manuscript VersionAdobe PDF (256.35 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Cutler, RL https://orcid.org/0000-0002-3236-8366	en_US
dc.contributor.author	Der Linden, NV	en_US
dc.contributor.author	Benrimoj, SIC https://orcid.org/0000-0001-9768-7838	en_US
dc.contributor.author	Fernandez-Llimos, F https://orcid.org/0000-0002-8529-9595	en_US
dc.contributor.author	Garcia-Cardenas, V https://orcid.org/0000-0003-3770-4557	en_US
dc.date.available	2020-05-25T19:11:30Z
dc.date.issued	2019-06-01	en_US
dc.identifier.citation	Journal of Comparative Effectiveness Research, 2019, 8 (8), pp. 555 - 567	en_US
dc.identifier.issn	2042-6305	en_US
dc.identifier.uri	http://hdl.handle.net/10453/133740
dc.description.abstract	© 2019 Future Medicine Ltd. Aim: To develop a standardized framework determining the economic impact of medication nonadherence. Materials & methods: Secondary analysis of existing literature reported cost data, aggregating cost outcome indicators. Weighted-average cost analysis performed, determining the proportional contribution to total cost. Results: Direct costs were reported in 92% of studies and indirect costs in 4% of studies. Three most utilized cost categories were hospital (68%), primary care (18%) and pharmacy costs (72%). Average unadjusted direct costs ranged from $625 to $154,203 contributing to 88% of the total cost; adjusted medical costs ranged from $565 to $56,313 representing 96% of the total cost. Conclusion: The medication adherence cost estimation framework enables the comparison of costing studies, facilitating informed health policy decision-making based on consistent evidence and terminology.	en_US
dc.relation.ispartof	Journal of Comparative Effectiveness Research	en_US
dc.relation.isbasedon	10.2217/cer-2018-0099	en_US
dc.title	An evidence-based model to consolidate medication adherence cost estimation: The medication adherence cost estimation framework	en_US
dc.type	Journal Article
utslib.citation.volume	8	en_US
utslib.for	1117 Public Health and Health Services	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Business
pubs.organisational-group	/University of Technology Sydney/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Strength - CHERE - Centre for Health Economics Research and Evaluation
utslib.copyright.status	open_access	*
pubs.issue	8	en_US
pubs.publication-status	Published	en_US
pubs.volume	8	en_US

Abstract:

© 2019 Future Medicine Ltd. Aim: To develop a standardized framework determining the economic impact of medication nonadherence. Materials & methods: Secondary analysis of existing literature reported cost data, aggregating cost outcome indicators. Weighted-average cost analysis performed, determining the proportional contribution to total cost. Results: Direct costs were reported in 92% of studies and indirect costs in 4% of studies. Three most utilized cost categories were hospital (68%), primary care (18%) and pharmacy costs (72%). Average unadjusted direct costs ranged from $625 to $154,203 contributing to 88% of the total cost; adjusted medical costs ranged from $565 to $56,313 representing 96% of the total cost. Conclusion: The medication adherence cost estimation framework enables the comparison of costing studies, facilitating informed health policy decision-making based on consistent evidence and terminology.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/133740